Evidence map›Paper›PMID 39418135›Full record

ArticleTherapeutic advances in respiratory disease

Optimizing the safety and efficacy of the awake venovenous extracorporeal membrane oxygenation in patients with COVID-19-related ARDS.

Peter Sklienka, Filip Burša, Michal Frelich, Jan Máca, Vojtech Vodička, Hana Straková, Markéta Bílená, Tereza Romanová, Hana Tomášková

Abstract read
In one paragraph

Article in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Peter SklienkaDepartment of Anesthesiology and Intensive Care Medicine, University Hospital of Ostrava, 17. listopadu 1790, Ostrava 70800, Czech Republic.ORCID 0000-0002-0330-5323
Filip BuršaDepartment of Anesthesiology and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic.
Michal FrelichDepartment of Anesthesiology and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic.
Jan MácaDepartment of Anesthesiology and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic.
Vojtech VodičkaDepartment of Anesthesiology and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic.
Hana StrakováDepartment of Anesthesiology and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic.
Markéta BílenáDepartment of Anesthesiology and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic.
Tereza RomanováDepartment of Anesthesiology and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic.
Hana TomáškováDepartment of Epidemiology and Public Health, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMaintaining the patient awake and not intubated during the venovenous extracorporeal membrane oxygenation (VV ECMO) reduces the risk of ventilation-induced lung injury in patients with ARDS. Currently, there is a lack of data on outcomes and complications associated with the awake ECMO approach.

objectivesTo evaluate outcomes and the occurrence of complications of awake ECMO approach guided by local safety protocol comprising ultrasound-guided cannulation, argatroban-based anticoagulation, respiratory support, and routine sedation targeted to reduce respiratory effort and keeping nurse-to-patient ratio of 1:1.

designA single-center retrospective case series analysis.

methodsConsecutive patients with COVID-19-related acute respiratory distress syndrome (ARDS) (CARDS) treated by full awake VV ECMO approach from April 2019 to December 2023 were eligible.

resultsOur center treated 10 patients (mean age 54.7 ± 11.6 years) with CARDS with an awake ECMO approach. The reasons for awake ECMO included the presence of barotrauma in six patients, a team consensus to prefer awake ECMO instead of mechanical ventilation in three patients, and the patient's refusal to be intubated in one case. Before ECMO, patients were severely hypoxemic, with a mean value of Horowitz index of 48.9 ± 9.1 mmHg and a mean respiratory rate of 28.8 ± 7.3 breaths per minute on high-flow nasal cannula or noninvasive ventilation support. The mean duration of awake VV ECMO was 558.0 ± 173.6 h. Seven patients (70%) were successfully disconnected from ECMO and fully recovered. Intubation from respiratory causes was needed in three patients (30%), all of whom died eventually. In total, three episodes of delirium, two episodes of significant bleeding, one pneumothorax requiring chest tube insertion, and one oxygenator acute exchange occurred throughout the 5580 h of awake ECMO. No complications related to cannula displacement or malposition occurred.

conclusionThe awake ECMO strategy guided by safety protocol appears to be a safe approach in conscious, severely hypoxemic, non-intubated patients with COVID-19-related ARDS.

Indexed as

COVID-19Extracorporeal Membrane OxygenationRespiratory Distress SyndromeWakefulnessAdultAgedAnticoagulantsArginineFemaleHumansMaleMiddle AgedPipecolic AcidsRetrospective StudiesSulfonamidesTreatment OutcomeAnticoagulantsargatrobanArgininePipecolic AcidsSulfonamidesacute respiratory distress syndromeawake venovenous extracorporeal membrane oxygenationbleedingdeliriumpatient self-inflicted lung injury

Identifiers

PMID39418135
PMCPMC11489919

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.